Scarica l'app Stockscreener
16.63
0.83%
-0.1724
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness - Yahoo Finance
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Sarepta Therapeutics Inc (MEX:SRPT) Stock Price, Trades & News - GuruFocus
Sarepta's Q1 earnings & sales beat estimates, '26 outlook maintained - MSN
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys - MSN
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - TradingView
1SRPT.MI Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (BIT:1SRPT) - ChartMill
Understanding the Setup: (SRPT) and Scalable Risk - Stock Traders Daily
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
My Top 3 Biotech Stocks for May 2026 - The Motley Fool
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock - Insider Monkey
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - FinancialContent
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $19 - Moomoo
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII
Rare Disease Therapeutics Market 2025-2033 | Market Growth - openPR.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 24.58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Neuromuscular Disease Therapeutics Market to Reach USD 45.62 - openPR.com
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
Sarepta Therapeutics (SRPT) Q1 earnings and revenues top estimates - MSN
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $19 - Moomoo
Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? - Eastern Progress
SRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growth - MSN
Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission - statnews.com
We Don't Think Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Should Make Shareholders Too Comfortable - Moomoo
Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft Foundations - Yahoo Finance
Sarepta Therapeutics stock (US8036071004): Q1 earnings beat estimates amid share price decline - AD HOC NEWS
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News - simplywall.st
SRPT Stock Price Prediction 2025-2026 | Sarepta Therapeutics Inc Forecast - 24/7 Wall St.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Business Wire
Sarepta Therapeutics (NASDAQ: SRPT) files Form 13F showing 1 entry - Stock Titan
Splicing Patent Eligibility: The Federal Circuit Restores § 101 Eligibility for Engineered Cells in 'REGENXBIO v. Sarepta' - Law.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Evaluating the 10.25% Potential Upside in a Challenging Market - DirectorsTalk Interviews
The Technical Signals Behind (SRPT) That Institutions Follow - Stock Traders Daily
Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones - Sahm
A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress - Yahoo Finance
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo
Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says - Moomoo
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):